Dane Leone
Stock Analyst at Raymond James
(1.23)
# 3,659
Out of 5,169 analysts
69
Total ratings
33.96%
Success rate
-5%
Average return
Main Sectors:
Stocks Rated by Dane Leone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Strong Buy | $29 → $19 | $9.93 | +91.34% | 3 | Aug 8, 2025 | |
| XLO Xilio Therapeutics | Maintains: Outperform | $84 → $56 | $7.60 | +636.84% | 3 | Nov 8, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $45 | $8.28 | +443.48% | 2 | Feb 21, 2024 | |
| RVMD Revolution Medicines | Initiates: Outperform | $30 | $98.11 | -69.42% | 1 | Nov 16, 2023 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $950 | $744.12 | +27.67% | 10 | Nov 3, 2023 | |
| NKTX Nkarta | Upgrades: Strong Buy | $13 | $2.24 | +480.36% | 5 | Oct 18, 2023 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $29 → $46 | $70.12 | -34.40% | 2 | Jul 18, 2023 | |
| GLPG Galapagos NV | Upgrades: Outperform | $69 | $32.17 | +114.49% | 5 | May 8, 2023 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $5 → $8 | $5.32 | +50.38% | 2 | Nov 10, 2022 | |
| OCUL Ocular Therapeutix | Maintains: Strong Buy | $29 → $14 | $8.49 | +64.90% | 5 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $58 | $11.59 | +400.43% | 4 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $70 | $11.63 | +501.89% | 3 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.15 | - | 6 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $63 | $62.19 | +1.30% | 2 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $59.37 | - | 4 | Jun 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.82 | - | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $50 → $65 | $68.24 | -4.75% | 3 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $255 | $351.48 | -27.45% | 3 | Oct 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $32 | $3.76 | +751.06% | 2 | Sep 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $237.28 | - | 2 | Jul 21, 2017 |
Relay Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $19
Current: $9.93
Upside: +91.34%
Xilio Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $84 → $56
Current: $7.60
Upside: +636.84%
REGENXBIO
Feb 21, 2024
Reinstates: Outperform
Price Target: $45
Current: $8.28
Upside: +443.48%
Revolution Medicines
Nov 16, 2023
Initiates: Outperform
Price Target: $30
Current: $98.11
Upside: -69.42%
Regeneron Pharmaceuticals
Nov 3, 2023
Upgrades: Outperform
Price Target: $950
Current: $744.12
Upside: +27.67%
Nkarta
Oct 18, 2023
Upgrades: Strong Buy
Price Target: $13
Current: $2.24
Upside: +480.36%
BridgeBio Pharma
Jul 18, 2023
Maintains: Outperform
Price Target: $29 → $46
Current: $70.12
Upside: -34.40%
Galapagos NV
May 8, 2023
Upgrades: Outperform
Price Target: $69
Current: $32.17
Upside: +114.49%
Compass Therapeutics
Nov 10, 2022
Maintains: Outperform
Price Target: $5 → $8
Current: $5.32
Upside: +50.38%
Ocular Therapeutix
Nov 8, 2022
Maintains: Strong Buy
Price Target: $29 → $14
Current: $8.49
Upside: +64.90%
Oct 13, 2022
Upgrades: Strong Buy
Price Target: $58
Current: $11.59
Upside: +400.43%
Aug 29, 2022
Maintains: Outperform
Price Target: $54 → $70
Current: $11.63
Upside: +501.89%
Aug 10, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.15
Upside: -
Aug 5, 2022
Maintains: Outperform
Price Target: $54 → $63
Current: $62.19
Upside: +1.30%
Jun 6, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $59.37
Upside: -
Apr 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.82
Upside: -
Oct 8, 2021
Maintains: Strong Buy
Price Target: $50 → $65
Current: $68.24
Upside: -4.75%
Oct 26, 2020
Upgrades: Outperform
Price Target: $255
Current: $351.48
Upside: -27.45%
Sep 10, 2018
Assumes: Buy
Price Target: $32
Current: $3.76
Upside: +751.06%
Jul 21, 2017
Downgrades: Sell
Price Target: n/a
Current: $237.28
Upside: -